Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established class of antihyperglycaemic drugs used for the treatment of T2D, which have demonstrated improvements in glycaemic control and reductions in BW in patients with T2D [5,6]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.